The Clinical Study Of Risperidon On Metabolic Affection In Schizophrenia Patients

Objective:Explor the characteristics and related factors of weight gain caused by risperidone in schizophrenia patients. Explor the affection and related factors of risperidone on the metabolic indexes in schizophrenia patients.Methods:The first part:observasion on115schizophrenia patients while in hospital treated with risperidone for24weeks, measurement height, weight,and assessment of a positive and negative sydrome scale as well as the change in food intake, in sleep and in activities every2weeks.The second part:56cases hospitalized schizophrenia patients treated with risperidone for16weeks were observed waist circumference, blood pressure, and evaluated a positive and negative sydrome scale every2weeks,determinated fasting plasma glucose,2-hour postprandial blood glucose,blood lipids at the next day into group and at8weekend and16weekend after treatment,and36healthy persons as contrast group.Results:The first part:The incidence rate of weight gain was61.74%(71patients),91.55%of them occured within16weeks,the body mass index increased rapidly in4-12week in the weight gain group, the rising range was89.18%of the totale’s within16week,and no more than significance after20week(p>0.05);the factors of affected the rising rate of body mass index were taking antipsychotic drug history, family history of obesity, changes in food intake, baseline body mass index. The second part:The waist circumference, triglyceride and2hours postprandial blood glucose in the patients group after treatment were significant increased and hign density lipoprotein decreased significantly compared with those before treatment, the chang in value was significant difference as the contrast group(p<0.05), there were no significant difference before and after treatment on blood pressure and fasting plasma glucose (p>0.05); the incidence rate of metabolic sydrome was12.5%(7cases) in patients group, abnomal rates of waist circumference, triglyceride, hign density lipoprotein and2hours postprandial blood glucose were39.29%,21.43%, 12.50%, and19.64%, there were significant difference as the contrast group(p<0.05), abnomal rates of blood pressure and fasting plasma glucose were8.93%,5.36%, there were no significant difference as the contrast group(p>0.05); the dangerous factors on the occurrence of metabolic sydrome were family history of diabetes and age,on exceeding waist circumference,abnomal triglyceride, abnomal2hours postprandial blood glucose were the baseline waist circumference and family history of obesity, baseline triglyceride and baseline systolic pressure,the baseline waist circumference and age.Conclusion:The first part:Risperidone can cause a general weight gain of patients with schizophrenia, weight gain concentrates in the first4months after treatment, and is the fastest in the first3months, last for6months at least;it is proned to weight gain on the patiants who never uses antipsychotic drug, has grade I family history of obesity, increases in food intake after taking medcine and has slim body. The second part: Risperidone can cause abdominal obesity, glucose and lipid abnomal metabolism and metabolic sydrome; risperidone shoud be used carefully for the older and grade I family history of diabetes and obesity posture.